Gilead Sciences (GILD)
165.61
+6.41 (4.03%)
NASDAQ · Last Trade: Oct 30th, 2:47 AM EDT
News & Press Releases
What Gilead Sciences (GILD) Said on Its Q3 Earnings Callmarketbeat.com
Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove performance. The company also raised its full-year base business revenue outlook while outlining t
Via MarketBeat · October 29, 2026
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fallchartmill.com
Via Chartmill · October 29, 2026
Gilead Sciences (NASDAQ:GILD) Posts Q3 Beat but Shares Stay Flat as Raised Guidance Is Roughly In Linechartmill.com
Via Chartmill · October 29, 2026
Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion...
Via StockStory · October 29, 2026
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decadeinvestors.com
Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.
Via Investor's Business Daily · October 29, 2026
Gilead Sciences Announces Third Quarter 2026 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026.
By Gilead Sciences, Inc. · Via Business Wire · October 29, 2026
Gilead Sciences earnings: what to look for from GILD
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after the bell. Here’s what you need to know. Gilead Sciences...
Via StockStory · October 27, 2026
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?fool.com
BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.
Via The Motley Fool · October 27, 2026
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?fool.com
These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.
Via The Motley Fool · October 25, 2026
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?fool.com
Both of these biotech stocks could be appealing to income investors.
Via The Motley Fool · October 25, 2026
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?fool.com
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.
Via The Motley Fool · October 23, 2026
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.
By Gilead Sciences, Inc. · Via Business Wire · October 22, 2026
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management across these two rare and serious liver diseases.
By Gilead Sciences, Inc. · Via Business Wire · October 22, 2026
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?fool.com
Both of these ETFs look the part, but only one is truly the better buy for investors.
Via The Motley Fool · October 22, 2026
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Daymarketbeat.com
Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal cell carcinoma (RCC).
Chief Executive Officer Terry Rosen said the co
Via MarketBeat · October 21, 2026
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights into broader experiences of people living with HIV, as well as emerging antiviral programs.
By Gilead Sciences, Inc. · Via Business Wire · October 19, 2026
1 Unprofitable Stock with Exciting Potential and 2 We Find Risky
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Via StockStory · October 19, 2026
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?fool.com
The company's recent momentum continues unabated.
Via The Motley Fool · October 18, 2026
3 Inflated Stocks Walking a Fine Line
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Via StockStory · October 16, 2026
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.
By Gilead Sciences, Inc. · Via Business Wire · October 15, 2026
Top S&P500 movers in Wednesday's sessionchartmill.com
Via Chartmill · October 14, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · October 14, 2026
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lensfool.com
PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.
Via The Motley Fool · October 11, 2026
Better Biotechnology ETF: First Trust FBT vs. VanEck BBHfool.com
VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
Via The Motley Fool · October 10, 2026
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharmafool.com
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Via The Motley Fool · October 10, 2026